This is a preclinical/early-stage pipeline update with no hard financial catalyst. Monitor for a definitive licensing agreement or partnership announcement, which would provide concrete deal value. Until then, the stock is likely to trade on sentiment and broader biotech sector dynamics.
Price Chart
Executive Summary
CDT Equity announced that AZD5904, a myeloperoxidase inhibitor licensed from AstraZeneca, has entered the PCT phase for global IP protection. The asset has Phase 1 safety data in 181 subjects and is being positioned for out-licensing in idiopathic male infertility and oncology-associated infertility. This is a non-financial pipeline update with no revenue, earnings, or deal value disclosed.
Key Facts
- AZD5904 entered the PCT phase for global patent protection
- Asset originally licensed from AstraZeneca
- 181 subjects dosed across five Phase 1 studies with no drug-related adverse events
- Target indications: idiopathic male infertility and oncology-associated infertility
- Company is actively seeking out-licensing or strategic partnerships
- No financial terms, deal value, or revenue disclosed
Financial Impact
No financial figures disclosed; potential future licensing revenue is speculative
Risk Factors
- No guarantee of successful out-licensing or partnership
- Asset is still in early clinical stage; regulatory and commercial risks remain
- Company has a small market cap ($10M) and may face financing or Nasdaq listing challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288812 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $37.00 $1.40 | ▲ +96.23% | ▲ +97.41% | $1.25 (+96.62%) |
Jul 31, 2026 9w ago | 8-K | $2.87 $1.68 | ▲ +41.36% | ▲ +42.60% | $1.25 (+56.37%) |
Jul 16, 2026 11w ago | 8-K | $0.3550 $3.15 | ▼ −785.92% | ▼ −782.30% | $1.25 (−252.11%) |
Jun 29, 2026 13w ago | 8-K | $0.5600 $2.85 | ▼ −408.04% | ▼ −409.06% | $1.25 (−123.21%) |
Jun 16, 2026 15w ago | 8-K | $0.6930 $0.3550 | ▲ +48.77% | ▲ +50.09% | $1.25 (−80.38%) |
May 6, 2026 21w ago | Press Release | $2.26 $0.8050 | ▼ −64.38% | ▼ −67.16% | $1.25 (−44.69%) |
Mar 4, 2026 30w ago | Press Release | $17.70 $5.10 | ▼ −71.19% | ▼ −66.77% | $1.25 (−92.94%) |
Feb 24, 2026 31w ago | 8-K | $17.25 $10.88 | ▼ −36.96% | ▼ −31.72% | $1.25 (−92.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access